The case for & against
Bull & Bear analysis
Theriva Biologics (NASDAQ: THER) specializes in developing oncolytic virus therapies aimed at treating difficult-to-manage cancers, with a significant focus on pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma. Theriva leverages its proprietary viral technology, VCN01, which is designed to selectively replicate in tumor cells, enhance immune responses, and address substantial unmet medical needs in the oncology sector. The company's strategic focus on innovative treatment approaches positions it favorably within the rapidly evolving cancer therapeutics landscape.
Bull says
- ↑$23.2 M cash supports operations through Q1 2025
- ↑VARAGE Phase II enrollment on track to finish by H1 2024
- ↑U.S. & EU orphan designations boost approval speed and exclusivity
- ↑VCN01’s oncolytic action degrades tumor matrix and enhances immunity
- ↑High growth outlook and strong liquidity underpin financial flexibility
- ↑Novel mechanism positions VCN01 ahead in the oncology pipeline
Bear says
- ↓2023 R&D spend rose to $14.3 M versus $23.2 M cash, increasing burn concerns
- ↓December FDA meeting carries risk of delays or negative feedback
- ↓VARAGE trial efficacy shortfalls could jeopardize future funding
- ↓Negative profitability and earnings yield signal weak income conversion
- ↓High short interest reflects growing investor skepticism
- ↓Analyst downgrades imply muted growth expectations ahead
Investment themes with TOVX
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q4 2022 · Mgmt. Guidance
Transcript signals
Bull points
- During the full year of 2022 and the first few months of 2023, we continue to make significant progress across our oncology portfolio.
- With a cash runway into the third quarter of 2024, we believe we're well positioned to execute on our corporate objectives and reach multiple value enhancing milestones throughout this year.
- We expect 2023 to be an important year for the advancement of our clinical programs that should continue to position Theriva at the forefront of oncolytic virus development.
Bear points
- General administrative expenses increased to $9.9 million for the year end December 31, 2022 from $6.5 million for the year ended December 31, 2021. This increase of approximately 50.8% is primarily comprised of increased expense related to the fair value of contingent consideration, higher insurance costs, additional salary and benefits related to new headcount, public relations expense, and VCNO administrative expenses not included in the prior year.
- General administrative expenses increased to $9.9 million for the year end December 31, 2022 from $6.5 million for the year ended December 31, 2021. This increase of approximately 50.8% is primarily comprised of increased expense related to the fair value of contingent consideration, higher insurance costs, additional salary and benefits related to new headcount, public relations expense, and VCNO administrative expenses not included in the prior year, offset by a decrease in consulting and legal costs related to the VCN acquisition.